Key result
Nucleoside RNA polymerase inhibitors show potential as anti-SARS-CoV-2 therapies in computational analyses.
Why the study?
There are no approved vaccines or drugs targeting human coronaviruses, and the COVID-19 outbreak emphasized an urgent need for therapeutic interventions.
Computational modeling suggests existing broad-spectrum RNA polymerase inhibitors may be feasible therapeutic candidates against SARS-CoV-2.
Hypothesis-generating for nucleoside inhibitors in SARS-CoV-2; experimental validation required before any clinical consideration.
Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.
No takes yet. Share an insight, caveat, or question.
Neogi et al. (2020) studied COVID-19 (SARS-CoV-2 infection). Broad-spectrum RNA polymerase inhibitors was evaluated on Feasibility as anti-SARS-CoV-2 drugs targeting main RNA polymerase. Computational and bioinformatics analyses suggest that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: